TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00678561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment once daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment twice daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment twice daily for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Topical treatment twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Topical treatment once daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vehicle
Description: Topical treatment twice daily for 28 days
Study: NCT00004031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV every 21 days

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: 375 mg/m2 IV every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone marrow ablation with stem cell support

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT01282216

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: 1440 ELISA units, or 1 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: 1440 ELISA units, or 1 mL, IM
Study: NCT03444909

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrophysiological device (Micromed)
Description: Monitoring of 20 min with the cardiotocograph

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrophysiological device (Micromed)
Description: Monitoring of 20 min with the cardiotocograph
Study: NCT01282216

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: 0.5 mL IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV13
Description: 0.5 mL IM
Study: NCT00437034

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: Given IV
Study: NCT04143412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tritace (Ramipril 10 mg)
Description: Stratified randomized clinical trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tritace (Ramipril 10 mg)
Description: Stratified randomized clinical trial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tritace (Ramipril 10 mg)
Description: Stratified randomized clinical trial
Study: NCT02456922

Intervention type: DEVICE
Group type: OTHER
Intervention: Harmony 1 Sensor
Description: Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
Study: NCT02066012

Intervention type: OTHER
Intervention: dysmetabolic iron overload syndrome

Intervention type: OTHER
Intervention: dysmetabolic iron overload syndrome

Intervention type: OTHER
Intervention: dysmetabolic iron overload syndrome
Study: NCT05036564

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lumbar puncture
Description: A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar puncture
Description: A lumbar puncture (spinal tap) is performed in patient lower back, in the lumbar region.~During a lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid (CSF). This is the fluid that surrounds brain and spinal cord to protect them from injury.~This procedure is usually performed at the time of diagnosis for disease staging and/or repeated in the course of the disease history, only if positive or for clinical reasons (i.e. suspicious of relapse progression).~In this study sequential CSF and peripheral blood samples of study population will be collected also at different time points, with the aim to improve diagnostics sensitivity, response assessment and monitoring early CNS relapse.
Study: NCT00222937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lessac-Madsen Resonant Voice Therapy
Description: Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Casper-Based Confidential Flow Therapy
Description: Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
Study: NCT01354015

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DRMS
Description: USE OF TEXT MESSAGING SYSTEM
Study: NCT02352116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional face-to-face education
Description: Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
Study: NCT02002494

Intervention type: OTHER
Intervention: Different positions
Description: Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
Study: NCT03497559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Classical music

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Music
Description: Classical music
Study: NCT01916304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine sodium new formulation
Description: Levothyroxine tablets
Study: NCT03429491

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Protein-free, LC n-3 PUFA-free juice based supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein
Description: Leucine-enriched whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine-enriched protein
Description: Leucine-enriched whey protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LC n-3 PUFA
Description: LC n-3 PUFA
Study: NCT02352116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care management
Description: Current standard of care at a major U.S. teaching hospital.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care management
Description: Current standard of care at a major U.S. teaching hospital.
Study: NCT03717038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sym004
Description: Sym004 is a 1:1 mixture of two recombinant mAbs (futuximab and modotuximab) which bind specifically to non-overlapping epitopes located in the extracellular domain (ECD) of the EGFR.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: TAS-102 is a combination of trifluridine, a thymidine-based nucleic acid analogue, and tipiracil, a thymidine phosphorylase inhibitor.
Study: NCT02192944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin-piperaquine
Description: Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
Study: NCT04788914

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Active bamboo charcoal± probiotics
Description: Active bamboo charcoal 2g, TID probiotics 0.8g

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Active bamboo charcoal± probiotics
Description: Active bamboo charcoal 2g, TID probiotics 0.8g
Study: NCT02648191

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroCoach II Stim
Description: A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are active.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroCoach II Stim
Description: A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.~For this intervention, the stimulations are inactive.
Study: NCT02908529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination product of Atomoxetine and Oxybutynin
Description: Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 2 tablets
Description: Placebo 2 tablets 2 hours before sleep
Study: NCT03750734

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.
Study: NCT03477500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide and ATG
Description: Hematopoetic stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: Alemtuzumab (Lemtrada)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine Pill
Description: Cladribine (Mavenclad)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab (Ocrevus)
Study: NCT01042691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
Study: NCT04426552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
Study: NCT01243307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 (or placebo) followed by placebo (or CT327)
Description: During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT327 (or placebo) followed by placebo (or CT327)
Description: During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.~During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.
Study: NCT02376582

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA
Description: DNA co-administered with protein at month 0, 1 and 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DNA
Description: DNA co-administered with protein at month 0, 1 and 6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIDSVAX B/E
Description: Protein co-administered with DNA at month 0,1 and 6

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AIDSVAX B/E
Description: Protein co-administered with DNA at month 0,1 and 6
Study: NCT03338907

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxycarbon (5% CO2+ 95% O2)
Description: Oxycarbon will be administered by mechanical ventilation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycarbon (5% CO2+ 95% O2)
Description: Oxycarbon will be administered by mechanical ventilation
Study: NCT03277859

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SAA-TBI
Description: Yoga twice a week for 75 minutes for 8 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAA-TBI
Description: Yoga twice a week for 75 minutes for 8 weeks
Study: NCT00771654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phentermine
Description: Subjects will receive Phentermine 37.5mg everyday for one year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily for one year
Study: NCT02495636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1401
Description: CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-1401
Description: CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A 1200 mg will be administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPDL3280A
Description: MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
Study: NCT02511873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fycompa
Description: Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
Study: NCT05588024

Intervention type: DEVICE
Intervention: Head Up CPR based bundle of care
Description: All patients in this registry receive the intervention, a Head Up Cardiopulmonary Resuscitation (CPR) based bundle of care. This bundle of care includes the use of multiple FDA approved devices. The components of the Head Up CPR bundle are 1) a single or combination of CPR methods including manual, active-compression decompression CPR, or automated suction-cup based CPR 2) An impedance threshold device 3) An automated patient positioning device capable of elevating the head and thorax
Study: NCT00753207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: liquid chromatography

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Study: NCT02698358

Intervention type: DEVICE
Intervention: Epic stent (Boston Scientific)
Study: NCT04042883

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acute normovolemic hemodilution
Description: 500 ml of blood will be taken from the patient with simultaneous replacement with hydroxyethyl starch (HES 130/0.4) in another IV line
Study: NCT00869648

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extension
Description: After anaesthesia induction the head is placed in extension

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neutral head position
Description: After anaesthesia induction the head is placed in neutral position

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anaesthesiologist's position
Description: after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
Study: NCT02240888

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg Prevenar i.m.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg Prevenar i.m.
Study: NCT02632448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules
Study: NCT02240888

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg Prevenar i.m.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg Prevenar i.m.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg seasonal influenza vaccine i.m.
Study: NCT02632448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2880070
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)
Study: NCT02240888

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg seasonal influenza vaccine i.m.
Study: NCT02632448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 50 to 600 milligrams per square meter of body surface area (mg/m2)
Study: NCT02240888

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg seasonal influenza vaccine i.m.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 0,5 mg seasonal influenza vaccine i.m.